Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 9/20 | 0.59 |
| ▸ | BRD4 | O60885 | 3/20 | 0.59 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | BRD1 | O95696 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422084 | 0.86 | BRPF1 (0.65) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL28311122 | 0.79 | BRPF1 (0.56) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL9497110 | 0.78 | DAO (0.49) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL16932310 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL30538035 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL1948671 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL29213984 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL19231303 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL31743117 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL30873747 | 0.78 | BRPF1 (0.57) | BRPF1BRD4BRD9CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029055-B2 | OLED with hybrid emissive layer | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230033573-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2023-02-02 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-5401751-A | Enzyme inhibitors for 5-lipoxygenase | ZENECA LIMITED (GB) | 1995-03-28 | — | — | US | disclosed |
| US-5350754-A | Heterocyclic cycloalkanes | ZENECA LIMITED (GB) | 1994-09-27 | — | — | US | disclosed |
| US-5302603-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-04-12 | — | — | US | disclosed |
| US-5236919-A | Inhibitorsof enzyme 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| US-5217977-A | Lipoxygenase inhibitor for treating diseases medicated by leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| US-5196419-A | Lipoxygenase enzyme inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-23 | — | — | US | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| EP-0385679-A2 | Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385663-A2 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | BRPF1 3553/4885BRD4 2305/4885BRD9 3187/4885 |
| US-12029055-B2 | OLED with hybrid emissive layer | S1PR4, S1PR1, S1PR2 | BRPF1 239/4885BRD4 1185/4885BRD9 943/4885 |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | BRPF1 3623/4885BRD4 2116/4885BRD9 3031/4885 |
| US-20230278969-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | BRPF1 3553/4885BRD4 2305/4885BRD9 3187/4885 |
| US-20230033573-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | BRPF1 3553/4885BRD4 2305/4885BRD9 3187/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | BRPF1 3445/4885BRD4 600/4885BRD9 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.